Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Infections and Infectious Diseases Phase III
Netherlands 
Details:
The approval of Sinovac’s polio vaccine (sIPV) by the NMPA in China is a major milestone in the ongoing efforts towards global polio eradication & to reduce the vaccine-associated paralytic polio caused by oral polio vaccines, which are based on live attenuated polio viruses.
Lead Product(s): sIPV
Therapeutic Area: Infections and Infectious Diseases Product Name: sIPV
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Sinovac Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2021
Details:
The REVIVAL trial is a Phase III pivotal study evaluating AM-Pharma’s proprietary recombinant alkaline phosphatase, ilofotase alfa, for the treatment of patients with SA-AKI.
Lead Product(s): Recombinant Human Alkaline Phosphatase
Therapeutic Area: Infections and Infectious Diseases Product Name: Ilofotase Alfa
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2021
Details:
Eupolio was developed by Intravacc for technology transfer to manufacturers in low- and middle-income countries in the context of the global polio eradication initiative. Eupolio™ received the prequalification status from the WHO by the end of December.
Lead Product(s): Sabin-inactivated polio vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Eupolio
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2021
Details:
Under the agreement, HALIX will provide commercial manufacturing of drug substance at its state-of-the-art cGMP facility at the Leiden Bio Science Park in the Netherlands. To meet the increased demand, HALIX expands with two additional viral vector production lines.
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 08, 2020
